Sign in

    Mark Hitrik • Stifel

    Mark Hitrik is a Biotechnology Equity Research Associate at Stifel Financial, focusing on equity research for the biotechnology sector. He provides analytical coverage on companies within the biotech industry, contributing to research outputs that assist investors in evaluating emerging and established healthcare firms. Hitrik began his career in equity research and joined Stifel Financial as a research associate, advancing in the biotechnology coverage group. He maintains professional credentials applicable for equity research roles, including registration with FINRA and relevant securities licenses.

    Mark Hitrik's questions to Acumen Pharmaceuticals Inc (ABOS) leadership

    Mark Hitrik's questions to Acumen Pharmaceuticals Inc (ABOS) leadership • Q3 2024

    Question

    Mark Hitrik of Stifel inquired about the specifics of the data expected from the Phase I subcutaneous study of sabirnetug and asked for clarity on how the company plans to incorporate that formulation into future clinical studies.

    Answer

    CEO Daniel O'Connell explained that the Phase I study in healthy volunteers is designed to evaluate the pharmacokinetics (PK) and bioavailability of the subcutaneous dose compared to the intravenous (IV) version. He stated that it is premature to define the precise next steps for the subcutaneous program until they have analyzed this data.

    Ask Fintool Equity Research AI